Intrathecal delivery of recombinant adeno-associated virus 9
The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders. It is disclosed that administration of a non-ionic, low-osmolar contrast agent, together with a rAAV9 vector for the expression of Survival Motor Neuron protein, improves the survival of SMN mutant mice as compared to the administration of the expression vector alone.
1. A polynucleotide comprising nucleotides 980-3336 of SEQ ID NO:1.
2. A recombinant adeno-associated virus (rAAV) vector comprising the polynucleotide of claim 1 .
3. The rAAV vector of claim 2 , wherein the rAAV vector comprises a serotype 9 capsid.
4. The rAAV vector of claim 2 , wherein the vector comprises a self-complementary rAAV genome.
5. A DNA plasmid comprising the polynucleotide of claim 1 .
6. The DNA plasmid of claim 5 , further comprising a selectable marker.
7. The DNA plasmid of claim 5 , comprising SEQ ID NO:1.
8. A composition comprising the rAAV vector of claim 2 and a pharmaceutically acceptable carrier.
9. The composition of claim 8 , further comprising a non-ionic, low-osmolar contrast agent.
10. The composition of claim 9 , wherein the non-ionic, low-osmolar contrast agent is iobitridol, iohexol, iomeprol, iopamidol, iopentol, iopromide, ioversol or ioxilan.
11. The composition of claim 9 , wherein the non-ionic, low-osmolar contrast reagent is iohexol.
12. The composition of claim 8 , wherein the composition is suitable for intrathecal administration.
13. A method of delivering a polynucleotide comprising nucleotides 980-3336 of SEQ ID NO:1 to the central nervous system of a patient in need thereof, the method comprising intrathecal administration of the composition of claim 8 .
14. The method of claim 13 , wherein the polynucleotide is delivered to the brain.
15. The method of claim 13 , wherein the polynucleotide is delivered to the spinal cord.
16. The method claim 13 , wherein the polynucleotide is delivered to a glial cell.
17. The method of claim 16 , wherein the glial cell is an astrocyte.
18. The method of claim 13 , wherein the polynucleotide is delivered to a lower motor neuron.
19. A method of treating a neurological disease caused by a reduction in expression of survival motor neuron protein in a patient in need thereof.
20. The method of claim 19 , wherein the patient is put in the Trendelenberg position after intrathecal administration of the rAAV.
21. The method of claim 19 , wherein the neurological disease is spinal muscular atrophy.
22. A method of treating a neurological disease caused by a reduction in expression of survival motor neuron protein in a patient in need thereof comprising intrathecal administration of a composition comprising the rAAV vector of claim 2 in combination with a non-ionic, low-osmolar contrast agent.
23. The method of claim 22 , wherein the non-ionic, low-osmolar contrast agent is iohexol.
24. The method of claim 22 , wherein the rAAV vector and the non-ionic, low-osmolar contrast agent are provided in separate compositions, and are mixed prior to the intrathecal administration.
25. The method of claim 22 , wherein the neurological disease is spinal muscular atrophy.
26. A kit comprising a first composition comprising the rAAV vector of claim 2 and a second composition comprising a non-ionic, low-osmolar contrast agent.
27. The kit of claim 26 , further comprising instructions for mixing said compositions to form a mixed composition, and thereafter, intrathecally administering the mixed composition to a patient in need thereof.
28. A cell comprising the DNA plasmid of claim 5 .
29. A method of manufacturing a rAAV vector, comprising introducing the DNA plasmid of claim 5 into a cell, wherein said rAAV vector is produced.
30. The method of claim 29 , wherein the cell is a HeLa cell, a 293 cell, an MRC-5 cell, a WI-38 cell, a Vero cell, or a FRhL-2 cell.